Alessia Potenza

Milan, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

T cells dressed up with a dual HLA-restricted TCR targeting cathepsin G drive effective AML eradication.

T cells dressed up with a dual HLA-restricted TCR targeting cathepsin G drive effective AML eradication.

Journal: Blood
Published: July 07, 2025

T cells dressed up with a dual HLA-restricted TCR targeting cathepsin G drive effective AML eradication.

T cells dressed up with a dual HLA-restricted TCR targeting cathepsin G drive effective AML eradication.

Journal: Blood
Published: July 07, 2025

TIGIT disruption rescues the antitumor activity of low avidity TCR-engineered T cells by increasing TCR signal strength.

TIGIT disruption rescues the antitumor activity of low avidity TCR-engineered T cells by increasing TCR signal strength.

Journal: Nature communications
Published: April 15, 2025

Author Correction: Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B.

Author Correction: Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B.

Journal: Nature immunology
Published: September 17, 2024

Harnessing the tumor microenvironment to boost adoptive T cell therapy with engineered lymphocytes for solid tumors.

Harnessing the tumor microenvironment to boost adoptive T cell therapy with engineered lymphocytes for solid tumors.

Journal: Seminars in immunopathology
Published: December 04, 2023

Harnessing T cell exhaustion and trogocytosis to isolate patient-derived tumor-specific TCR.

Harnessing T cell exhaustion and trogocytosis to isolate patient-derived tumor-specific TCR.

Journal: Science advances
Published: December 01, 2023

TIM-3, LAG-3, or 2B4 gene disruptions increase the anti-tumor response of engineered T cells.

TIM-3, LAG-3, or 2B4 gene disruptions increase the anti-tumor response of engineered T cells.

Journal: Frontiers in immunology
Published: October 10, 2023

Epithelial ovarian cancer is infiltrated by activated effector T cells co-expressing CD39, PD-1, TIM-3, CD137 and interacting with cancer cells and myeloid cells.

Epithelial ovarian cancer is infiltrated by activated effector T cells co-expressing CD39, PD-1, TIM-3, CD137 and interacting with cancer cells and myeloid cells.

Journal: Frontiers in immunology
Published: April 26, 2023

Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells.

Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells.

Journal: Gut
Published: June 14, 2022

CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function.

CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function.

Journal: Science translational medicine
Published: February 09, 2022

Workflow for high-dimensional flow cytometry analysis of T cells from tumor metastases.

Workflow for high-dimensional flow cytometry analysis of T cells from tumor metastases.

Journal: Life science alliance
Published: November 24, 2021

Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B.

Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B.

Journal: Nature immunology
Published: April 18, 2021
Showing 1-12 of 14

Last Updated: 09/26/2026